RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors , FIH, MAD Study
Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
RBN-2397 inhibits PARP7, an enzyme that is switched on by cancer stresses, such as the toxins
in cigarette smoke. Cancer cells use PARP7 to hide from the immune system by stopping the
cell from sending a signal (Type 1 interferon) that tells the immune system that something is
wrong and to kill the cell. RBN-2397 has been shown in animal studies to inhibit tumor growth
and also shuts down the "don't kill me" signal the tumor is sending to evade the immune
system. As a PARP7 inhibitor RBN-2397 is different from drugs inhibiting PARP1, PARP2 and
PARP3 enzymes which are approved for the treatment of certain ovarian and breast cancers.
The primary purpose of this study is to determine the maximum tolerated dose (MTD) of orally
administered RBN-2397 in patients with advanced or metastatic solid tumors. This study will
also evaluate the safety and tolerability of RBN-2397, examine the pharmacokinetics (PK)
(measure how the body absorbs, breaks down and eliminates RBN-2397) and investigate whether
it has antitumor activity in solid tumor cancers.